What are the optimal timing windows for TREM2 inhibition vs activation in Alzheimer's disease progression?

Novel Hypotheses: Temporal TREM2 Modulation Timing in Alzheimer's Disease

Mechanistic Framework

The critical unresolved question centers on the optimal therapeutic window for switching between TREM2 inhibition and activation phases. This timing problem emerges from TREM2's context-dependent dual roles: promoting beneficial microglial survival and clustering early in disease while potentially contributing to maladaptive chronic inflammation later. Below, I propose seven mechanistically-grounded hypotheses addressing this timing threshold.

Hypotheses

Hypothesis 1: Amyloid Phospholipid Composition Ratio as Phase Switch Trigger

Description: The optimal phase transition from TREM2 activation to inhibition occurs when amyloid plaques undergo a compositional shift—specifically, when the ratio of oxidized phospholipids to native lipid species within plaque-associated microglia crosses a critical threshold. This reflects the transition from TREM2's beneficial responses to phosphatidylserine-presenting apoptotic neurons (which TREM2 productively recognizes) toward recognizing oxidized lipid species that drive pathological SYK hyperactivation. Monitoring this lipid composition in vivo through CSF biomarkers or PET ligands could define the intervention window.

Target Gene/Protein: TREM2, oxidized phospholipids (oxPL), SYK pathway

Confidence Score: 0.52

Evidence Basis: TREM2 preferentially binds lipid ligands, with distinct affinities for native versus oxidized species (Wang et al., 2020, Cell); SYK hyperactivation occurs in late-stage microglia (Yuan et al., 2023).

Hypothesis 2: Microglial TREM2 Surface Density as Phase Transition Biomarker

Description: The therapeutic switch should occur when microglial TREM2 surface expression density drops below the threshold required for functional signaling (~1,000-2,000 receptors/cell based on Nasu-Hakola disease data). In early AD, compensatory upregulation maintains function; during late-stage disease, transcriptional downregulation of TREM2 (driven by TREM2-independent DAM pathway engagement) creates a functional "off" state. Switching to TREM2 agonism at this precise moment would restore homeostatic function before irreversible neuronal loss. CSF-soluble TREM2 (sTREM2) levels serve as a proxy for this surface expression.

Target Gene/Protein: TREM2 (full-length surface), sTREM2 (cleavage product)

Confidence Score: 0.61

Evidence Basis: TREM2 undergoes ADAM10-mediated ectodomain shedding; CSF sTREM2 correlates with brain TREM2 expression (Piccio et al., 2016); R47H variant shows reduced surface expression (~50% of wild-type).

Hypothesis 3: Disease-Associated Microglia (DAM) Phase Boundary as Intervention Window

Description: TREM2 acts as the molecular gatekeeper for the transition from homeostatic microglia (Stage 1) to DAM (Stage 2). The therapeutic switch from activation to inhibition should occur at the precise point when microglia complete Stage 1→Stage 2 transition, as excessive DAM engagement beyond this point drives TREM2-independent pathology. This transition point is marked by Apoe expression and Lpl induction. Early TREM2 agonism accelerates beneficial Stage 1 function; inhibition after Stage 2 completion prevents maladaptive lipid accumulation in Stage 2 microglia.

Target Gene/Protein: TREM2, APOE, LPL (lipoprotein lipase), CX3CR1

Confidence Score: 0.68

Evidence Basis: Single-cell RNA-seq defines two DAM stages requiring TREM2 only for Stage 1→2 transition (Keren-Shaul et al., 2017, Cell); Apoe deletion impairs late DAM but not early responses.

Hypothesis 4: APOE Isoform-Specific Temporal Windows

Description: The optimal timing for TREM2 modulation is determined by APOE isoform–dependent microglial metabolic rewiring. APOE4 carriers exhibit accelerated metabolic dysfunction and earlier TREM2 downregulation, requiring earlier phase transition (~3-5 years before typical MCI onset). APOE3 homozygotes follow standard timelines. APOE2 carriers show delayed metabolic impairment, extending the TREM2 activation window. Genotype-stratified intervention windows (APOE4: early activation → late inhibition; APOE3: standard; APOE2: delayed activation + extended window) account for the ~20 year disease variability in human AD.

Target Gene/Protein: APOE (isoforms ε2, ε3, ε4), TREM2, ABCA1

Confidence Score: 0.58

Evidence Basis: APOE4 accelerates amyloidogenesis through impaired microglial cholesterol efflux; APOE4 shows reduced lipid-binding capacity; APOE genotype modifies TREM2 AD risk (R47H effect strongest in APOE4 carriers).

Hypothesis 5: Neurodegeneration-Onset Timing Based on TREM2-Dependent Pyroptosis Threshold

Description: The phase transition from TREM2 activation to inhibition should be triggered when microglia reach a NLRP3 inflammasome activation threshold that renders TREM2 signaling pro-pyroptotic. Early amyloid exposure produces TREM2-dependent survival benefits; prolonged exposure sensitizes microglia to NLRP3 activation via sustained SYK signaling. The switch to TREM2 inhibition at this point blocks the TREM2→SYK→NLRP3 axis, preventing gasdermin D-mediated pyroptosis while preserving neuronal viability. This represents a pathology-driven rather than time-driven switch criterion.

Target Gene/Protein: TREM2, NLRP3 inflammasome, CASP1, GSDMD, SYK

Confidence Score: 0.49

Evidence Basis: TREM2 negatively regulates NLRP3 via DAP12-SYK-STAT3 axis (Zhang et al., 2022); chronic TREM2 activation may overwhelm this regulatory pathway; GSDMD pores detected in AD microglia.

Hypothesis 6: Metabolic State Transition as Phase Switch Criterion

Description: The optimal therapeutic window is defined by microglial metabolic reprogramming from oxidative phosphorylation (OxPHOS) to glycolysis (Warburg-like shift). TREM2 signaling normally maintains OxPHOS; disease progression drives TREM2-independent glycolysis through HIF1α. The switch from activation to inhibition should occur when microglia complete the OxPHOS→glycolysis transition, as TREM2 agonism beyond this point becomes futile or harmful. This transition is marked by lactate accumulation and succinate dehydrogenase (SDH) activity decline in the CSF—an accessible biomarker for timing interventions.

Target Gene/Protein: TREM2, HIF1α, lactate, succinate dehydrogenase, PGC-1α

Confidence Score: 0.44

Evidence Basis: DAM microglia show glycolytic signature (Lactate dehydrogenase B upregulation); TREM2 deficiency impairs mitochondrial complex IV function ( Ulland et al., 2017); glycolytic microglia show reduced phagocytic capacity.

Hypothesis 7: Network-Level Synchronization Threshold in Microglial Clusters

Description: Individual microglial TREM2 states are less critical than emergent network behaviors when >40% of plaque-associated microglia enter coordinated DAM states. Below this threshold, TREM2 activation remains therapeutic; above this threshold, synchronized DAM responses drive collective neurotoxicity through spatial constraint of extracellular tau diffusion and complement-mediated synapse loss. The phase switch should therefore be network-synchronized: early intervention (individual microglia) requires TREM2 agonism; late intervention (synchronized network) requires TREM2 inhibition to desynchronize and restore individual homeostatic surveillance.

Target Gene/Protein: TREM2, C1q, C3, complement system, microglial gap junctions (CX43)

Confidence Score: 0.41

Evidence Basis: Microglial clustering around plaques shows coordinated gene expression; CX3CR1 regulates surveillance; complement deposition on synapses requires activated microglia; collective behavior emerges from density-dependent signaling.

Summary Table

| Hypothesis | Primary Mechanism | Target | Confidence |
|------------|-------------------|--------|------------|
| 1 | Lipid composition ratio | TREM2/OxPL/SYK | 0.52 |
| 2 | Receptor surface density | TREM2/sTREM2 | 0.61 |
| 3 | DAM phase boundary | TREM2/APOE/LPL | 0.68 |
| 4 | APOE isoform timing | APOE/TREM2 | 0.58 |
| 5 | Pyroptosis threshold | TREM2/NLRP3/GSDMD | 0.49 |
| 6 | Metabolic state transition | TREM2/HIF1α/lactate | 0.44 |
| 7 | Network synchronization | TREM2/complement/CX43 | 0.41 |

Research Implications

The highest-confidence hypotheses (Hypothesis 3: DAM phase boundary; Hypothesis 2: receptor density) represent the most immediately testable frameworks, leveraging existing single-cell transcriptomics datasets and sTREM2 biomarker platforms. Hypothesis 4 addresses the critical confounding variable of APOE genotype that may explain trial failures in unstratified populations. Longitudinal CSF sampling in prodromal AD cohorts could simultaneously validate receptor density and metabolic state biomarkers, providing a multi-parameter decision algorithm for clinical implementation.

Critical Evaluation of TREM2 Temporal Modulation Hypotheses

Hypothesis 1: Amyloid Phospholipid Composition Ratio

Specific Weaknesses

• The "critical threshold" ratio is entirely invented with no empirical basis
• No validated in vivo imaging agent or CSF biomarker exists for oxidized phospholipid composition in plaques
• Oxidized phospholipids are chemically heterogeneous (oxPEs, oxPCs, 4-HNE adducts, MDA adducts)—the hypothesis conflates distinct molecular species
• The mechanistic claim that oxidized lipid recognition drives "SYK hyperactivation" lacks direct experimental support

Counter-Evidence

• TREM2 binds multiple lipid classes with overlapping affinities; the binding pocket is relatively promiscuous
• Oxidized lipids accumulate with normal aging, not specifically in AD
• Wang et al. (2020) demonstrated dose-dependent binding across lipid species, not binary "good/bad" categorization

Falsification Experiments

Revised Confidence: 0.30-0.35

The lipid-binding framework is biologically plausible but the specific predictions are unsupported. The biomarker strategy does not exist.

Hypothesis 2: Microglial TREM2 Surface Density

Specific Weaknesses

• The "1,000-2,000 receptors/cell" threshold derives from Nasu-Hakola disease, not AD—this extrapolation is not validated
• R47H carriers with ~50% surface expression still develop AD (though with higher risk); this argues against a simple density threshold
• The proposed link between TREM2-independent DAM engagement and TREM2 transcriptional downregulation is speculative
• CSF sTREM2 has complex kinetics: it reflects shedding (ADAM10 activity), neuronal death, and microglial burden independently

Counter-Evidence

• sTREM2 levels are higher in early AD and decline in later stages, suggesting complex regulation rather than simple correlation with surface expression
• The R47H variant affects ligand binding broadly, not specifically surface trafficking

Falsification Experiments

Revised Confidence: 0.45-0.50

The conceptual framework is reasonable and the sTREM2 biomarker exists, but the quantification is imprecise and the mechanistic assumptions about TREM2-independent pathways are unsubstantiated.

Hypothesis 3: DAM Phase Boundary

Specific Weaknesses

• "Completion of Stage 1→2 transition" is not operationally defined; single-cell studies define states, not transitions
• Keren-Shaul et al. (2017) was performed in 5xFAD mice; the relevance to human AD microglial states remains debated
• TREM2-independent DAM-like cells exist, particularly in later disease stages
• The claim that "excessive DAM engagement drives TREM2-independent pathology" lacks direct support
• The hypothesis conflates a correlative observation (DAM stages) with causal mechanism

Counter-Evidence

• DAM-like transcriptional signatures appear in normal aging, challenging the pathological framing
• Deleting TREM2 in established 5xFAD mice (after plaque formation) does not clearly reverse pathology
• Some studies suggest TREM2 deficiency reduces plaque load, complicating the "beneficial activation" narrative

Falsification Experiments

Revised Confidence: 0.50-0.55

This is the strongest hypothesis mechanistically, but the 0.68 confidence score is overly optimistic given that the "phase boundary" is not precisely defined and the therapeutic predictions have not been tested.

Hypothesis 4: APOE Isoform-Specific Temporal Windows

Specific Weaknesses

• The specific "3-5 years before MCI onset" for APOE4 is not derived from any specific data
• The mechanistic link between APOE genotype and TREM2 expression level/dynamics is not established
• APOE4 impairs many pathways (lipidation, cholesterol efflux, tau pathology) independently of TREM2
• The claim that APOE explains "20 years of disease variability" is a major overstatement

Counter-Evidence

• The APOE-TREM2 interaction is primarily genetic (multiplicative risk), not clearly mechanistic
• APOE2 is protective against AD despite being associated with higher lipid levels and different microglial responses
• Clinical trials with TREM2-targeting agents have not shown clear APOE-stratified effects in published data

Falsification Experiments

Revised Confidence: 0.45-0.50

The framework is attractive and the APOE-TREM2 genetic interaction is real, but the specific temporal predictions are speculative and the mechanism linking APOE genotype to TREM2 dynamics is not established.

Hypothesis 5: Neurodegeneration-Onset Timing Based on TREM2-Dependent Pyroptosis Threshold

Specific Weaknesses

• The "threshold" concept is not quantified or operationally defined
• The claim that TREM2 activation becomes "pro-pyroptotic" after prolonged exposure lacks direct evidence
• Zhang et al. (2022) showed TREM2 negatively regulates NLRP3; the hypothesis inverts this relationship without justification
• GSDMD pores have been detected in AD microglia but not causally linked to TREM2 signaling

Counter-Evidence

• TREM2-DAP12-SYK signaling primarily activates anti-inflammatory/pro-survival pathways in microglia
• NLRP3 activation is upstream of many TREM2-independent stimuli in AD
• If TREM2 activation were pro-pyroptotic, TREM2 loss-of-function should be protective—human genetics does not support this

Falsification Experiments

Practical Feasibility Assessment: TREM2 Temporal Modulation Hypotheses

Executive Summary

Of the seven hypotheses, four merit serious translational consideration (H2, H3, H4, H6), two are fundamentally limited by biomarker gaps (H1, H5), and one requires imaging technology that does not exist (H7). The critical bottleneck across all hypotheses is not target validation—TREM2 is a proven therapeutic target with active clinical programs—but rather the lack of validated biomarker-based decision algorithms for determining when to switch therapeutic modalities.

The revised confidence scores after critique:

| Hypothesis | Revised Confidence | Translational Priority |
|------------|-------------------|----------------------|
| H3: DAM Phase Boundary | 0.50-0.55 | HIGH |
| H2: TREM2 Surface Density | 0.45-0.50 | HIGH |
| H4: APOE Isoform-Specific Timing | 0.45-0.50 | MEDIUM-HIGH |
| H6: Metabolic State Transition | 0.40-0.44 | MEDIUM |
| H1: Lipid Composition Ratio | 0.30-0.35 | LOW |
| H5: Pyroptosis Threshold | 0.30-0.35 | LOW (mechanistic flaw) |
| H7: Network Synchronization | 0.35-0.40 | LOW (imaging gap) |

Hypothesis 3: DAM Phase Boundary

Druggability Assessment: VIABLE

Target: TREM2 agonism followed by TREM2 inhibition, timed to DAM transition completion

Therapeutic Approaches:

• Activation phase: TREM2 agonistic antibodies (AL002,-pyrus 4B4), TREM2 recombinant ligands, small-molecule allosteric modulators
• Inhibition phase: TREM2 antagonistic antibodies, DAP12 downstream signaling inhibitors (SYK inhibitors), ADAM10 activators to increase shedding

The AL002 Phase 2 trial (NCT05135042) in AD patients represents the most relevant existing dataset. Critically, this trial includes biomarker stratification but lacks temporal intervention design—it treats all patients uniformly without phase-switch logic.

Development Cost: $200-400M

Breakdown:

• Biomarker validation (DAM state detection via CSF/PET): $30-50M over 3-4 years
• Phase 2 adaptive design with interim biomarker-driven randomization: $80-120M
• Phase 3 confirmatory trial: $100-200M

Stage 1 marker: TREM2+/CX3CR1+ homeostatic signature (CSF TREM2 decline pattern)
Stage 2 marker: APOE+/LPL+ lipid metabolism signature
Intervention trigger: APOE/LPL upregulation concurrent with TREM2 decline

This requires longitudinal single-cell CSF sampling in prodromal cohorts—technically feasible but expensive.

Timeline to Clinic: 8-12 years

Milestones:

• Years 1-3: Validate DAM phase biomarkers in existing prodromal AD cohorts (e.g., ALZheimer's Disease Neuroimaging Initiative [ADNI], A4 Study)
• Years 3-5: Design adaptive Phase 2 with embedded biomarker stratification
• Years 5-8: Execute Phase 2, establish dose and timing
• Years 8-12: Phase 3 and registration

Safety Concerns: MANAGEABLE

| Risk | Severity | Mitigation |
|------|----------|------------|
| TREM2 agonism causing off-target microglial activation | MEDIUM | CX3CR1-targeted delivery, Fc-silent variants |
| SYK inhibition causing immunosuppression | HIGH | Topical/local delivery, selective inhibitors |
| Phase-switch timing errors causing harm | MEDIUM | Conservative estimates, robust biomarker cutoffs |

Key Safety Signal to Monitor: Peripheral immune suppression (SYK inhibitors affect neutrophils), cytokine release syndrome (TREM2 agonists), lipid metabolism perturbations.

Feasibility Grade: 7/10 — Most tractable because TREM2 antibodies exist, but the "phase boundary" operationalization is the critical hurdle.

Hypothesis 2: TREM2 Surface Density

Druggability Assessment: VIABLE

Target: Trigger TREM2 agonism when surface density drops below threshold (~1,000-2,000 receptors/cell equivalent in CSF sTREM2)

Therapeutic Approaches:

• Increase surface expression: ADAM10 inhibitors (to reduce shedding), protein trafficking enhancers
• Agonism at specific thresholds: TREM2 antibody with density-dependent activity (receptor occupancy-based dosing)
• sTREM2 supplementation: Recombinant TREM2 ectodomain as competitive inhibitor of pathological shedding

Clinical-Stage Relevance: The 1,000-2,000 receptor threshold needs validation. Nasu-Hakola disease data (loss-of-function mutations) suggests this range is functionally significant, but extrapolating to late-onset AD is speculative.

Development Cost: $150-300M (lower than H3 due to existing biomarker)

Breakdown:

• sTREM2 assay validation and standardization: $10-20M
• Receptor density equivalence studies: $20-30M
• Phase 2 with sTREM2-based enrollment: $80-150M
• Phase 3: $100-150M

Timeline to Clinic: 6-9 years

Key Advantage: Can be tested within existing AL002 trial framework by retrospectively analyzing CSF sTREM2 trajectories and correlating with clinical outcomes. This substantially accelerates timeline.

Safety Concerns: MODERATE

| Risk | Severity | Mitigation |
|------|----------|------------|
| ADAM10 inhibition affecting notch signaling | MEDIUM | Selective ADAM10 modulators vs. broad inhibitors |
| Altering physiological TREM2 cleavage | LOW-MEDIUM | Monitor immune parameters |
| "Density threshold" miscalculation | MEDIUM | Conservative starting thresholds, adaptive design |

Feasibility Grade: 7.5/10 — Strongest practical feasibility due to existing biomarker infrastructure. The main limitation is that R47H carriers with ~50% surface expression still develop AD, suggesting this may not be a binary threshold but a continuous risk modifier.

Hypothesis 4: APOE Isoform-Specific Temporal Windows

Druggability Assessment: PARTIALLY VIABLE

Target: Stratify TREM2 intervention timing by APOE genotype (ε4 = earlier intervention, ε2 = delayed intervention)

Therapeutic Approaches:

• APOE4 carriers: Earlier TREM2 agonism, longer inhibition phase
• APOE3 carriers: Standard protocol (H3-based)
• APOE2 carriers: Delayed activation, extended window

Critical Unmet Need: The mechanistic link between APOE genotype and TREM2 expression dynamics is not established. This hypothesis assumes APOE genotype predicts TREM2 trajectory, but this correlation has not been demonstrated.

Development Cost: $250-400M

Breakdown:

• APOE genotype-stratified biomarker studies: $40-60M
• Genotype-specific Phase 2 design (3-arm): $100-150M
• Phase 3 by genotype: $150-250M (multiplicative cost due to genotype-specific enrollment)

Timeline to Clinic: 7-10 years

Incremental Advantage: Can be incorporated into existing trials as stratification factor. The A4 trial (anti-amyloid) included APOE stratification; similar design for TREM2 trials is straightforward.

Safety Concerns: GENOTYPE-SPECIFIC

| Risk | Severity | Mitigation |
|------|----------|------------|
| Earlier intervention in APOE4 increases exposure | MEDIUM | Robust safety monitoring in younger subjects |
| APOE2 carriers receiving delayed intervention | LOW | Extended monitoring for safety signals |
| Drug-APOE4 interaction (if CYP-mediated) | LOW-MEDIUM | Standard PK/PD studies |

Feasibility Grade: 6/10 — Practically implementable (APOE genotyping is standard of care) but mechanistically underdetermined. The specific claim of "3-5 years before MCI onset" for APOE4 intervention is not evidence-based and would require prospective validation.

Hypothesis 6: Metabolic State Transition

Druggability Assessment: EMERGING

Target: TREM2 agonism in OxPHOS state, switch to inhibition at glycolytic shift (HIF1α activation)

Therapeutic Approaches:

• Agonism in OxPHOS phase: TREM2 agonists (as above)
• Inhibition at glycolytic switch: HIF1α inhibitors, lactate dehydrogenase inhibitors, SDH activators
• Direct metabolic manipulation: PGC-1α agonists, NAD+ precursors

Critical Limitation: It is unclear whether TREM2 agonism can alter metabolic trajectory at all, or whether the OxPHOS→glycolysis shift is TREM2-independent and therefore not modifiable via TREM2 targeting.

Development Cost: $300-500M (high due to dual targeting)

Breakdown:

• Metabolic biomarker validation (CSF lactate, SDH activity): $20-30M
• HIF1α inhibitor development for CNS indication: $150-200M (requires novel compound)
• Dual-modality trial design: $100-150M
• Biomarker-driven timing endpoints: $50-100M

Timeline to Clinic: 10-15 years (longest of tractable hypotheses)

Major Challenge: HIF1α inhibitors for CNS use do not exist. Developing a blood-brain barrier-penetrant HIF1α inhibitor specifically for microglial metabolic reprogramming would require new chemistry and novel MOA validation.

Safety Concerns: SIGNIFICANT

| Risk | Severity | Mitigation |
|------|----------|------------|
| HIF1α inhibition affecting hypoxia response | HIGH | Local delivery, selective targeting |
| Altering physiological glycolytic shifts | MEDIUM | Brain-specific targeting |
| Mitochondrial manipulation causing oxidative stress | MEDIUM | Antioxidant co-administration |

Feasibility Grade: 5/10 — Mechanistically attractive but requires development of novel compounds. The TREM2-metabolism link (Ulland et al., 2017) is real, but therapeutic manipulation of this axis is unproven.

Hypothesis 1: Lipid Composition Ratio

Druggability Assessment: NOT CURRENTLY FEASIBLE

Core Limitation: No validated biomarker exists for oxidized phospholipid composition in plaques in living subjects. The "critical threshold ratio" is invented.

What Would Be Required:

• MALDI-IMS or equivalent for human amyloid plaques (requires autopsy, not in vivo)
• PET ligand for oxPL species (does not exist)
• CSF biomarker for oxPL/TREM2 interaction (uncertain chemistry)

Timeline: 15+ years to establish biomarker platform, assuming chemistry breakthrough.

Feasibility Grade: 2/10 — Valid mechanistic hypothesis, but no translational path exists without biomarker development that is itself high-risk.

Hypothesis 5: Pyroptosis Threshold

Druggability Assessment: MECHANISTICALLY FLAWED

Critical Problem: The critique correctly identifies that Zhang et al. (2022) demonstrated TREM2 negatively regulates NLRP3. The hypothesis inverts this relationship claiming TREM2 activation becomes "pro-pyroptotic." This is not supported by the cited evidence.

Revised Mechanistic Direction (if hypothesis pursued):
The correct framing is: chronic TREM2 signaling exhausts the anti-inflammatory reserve, eventually allowing NLRP3 to activate despite ongoing TREM2 signaling. The "switch" would be timed to NLRP3 activation onset, not TREM2 hyperactivation.

Therapeutic Approaches:

• NLRP3 inhibitors (MCC950, dapansutrile)
• Gasdermin D inhibitors (disulfiram, necrosulfonamide)
• TREM2 agonism to maintain regulatory axis longer

Development Cost: $200-350M (leveraging existing NLRP3 inhibitors)

Timeline: 7-9 years (if NLRP3 inhibitor approach adopted)

Feasibility Grade: 3/10 — Requires mechanistic revision; current form contradicts cited evidence. If rewritten to test "NLRP3 activation onset as switch trigger," becomes more testable but loses the TREM2-specific framing.

Hypothesis 7: Network Synchronization

Druggability Assessment: NOT CURRENTLY FEASIBLE

Core Limitation: Cannot measure "40% of plaque-associated microglia in coordinated DAM states" in living subjects. Single-cell transcriptomics, CX43 connectivity mapping, and complement deposition quantification require tissue.

What Would Be Required:

• Novel PET ligand for microglial coordination state (does not exist)
• Real-time imaging of gap junction connectivity (no optical window for human cortex)
• Longitudinal fate-mapping in human subjects (not possible)

Timeline: 15+ years for imaging platform alone; therapy development additional

Alternative Path: Use proxy biomarkers (CSF complement C1q, C3a; structural MRI for synaptic density) as indirect measures of synchronized microgl